Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese Local Pharmas See Innovative Products As Future Growth Driver - China Healthcare Investment Conference

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Fueled by the Chinese government's latest five-year plan that will promote innovation and increase exports of finished products, Chinese domestic companies are increasing their R&D efforts to ensure future growth, companies said during the second annual China Healthcare Investment conference March 23
Advertisement

Related Content

Traditional Chinese Medicines Seen As Global Growth Opportunity
Traditional Chinese Medicines Seen As Global Growth Opportunity
China's Tasly Focuses On Plant-based Medicines To Gain Entry To U.S.Market
China's Tasly Focuses On Plant-based Medicines To Gain Entry To U.S.Market
Jiangsu Hengrui Shifts From Generic Supplier To Innovative Company; Analysts See Shades Of Takeda In Transformation
Jiangsu Hengrui Shifts From Generic Supplier To Innovative Company; Analysts See Shades Of Takeda In Transformation
Pfizer China Country Manager Wu Xiaobing And General Manager For Commercial And Diversified Business Kevin Xiao On Expansion To Rural Markets In China: An Interview With PharmAsia News
Pfizer China Country Manager Wu Xiaobing And General Manager For Commercial And Diversified Business Kevin Xiao On Expansion To Rural Markets In China: An Interview With PharmAsia News
Expansion Into China's Lower-tier Cities Could Be Growth Driver For Big Pharma
Expansion Into China's Lower-tier Cities Could Be Growth Driver For Big Pharma
Advertisement
UsernamePublicRestriction

Register

SC077468

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel